Emerald Advisers LLC Sells 124,777 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Emerald Advisers LLC decreased its position in NeoGenomics, Inc. (NASDAQ:NEO) by 7.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,557,437 shares of the medical research company’s stock after selling 124,777 shares during the quarter. Emerald Advisers LLC owned 1.21% of NeoGenomics worth $25,667,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in NeoGenomics during the 4th quarter valued at $26,000. Versant Capital Management Inc raised its holdings in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the period. Quarry LP purchased a new stake in NeoGenomics during the 3rd quarter valued at $40,000. Smartleaf Asset Management LLC raised its holdings in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after buying an additional 2,787 shares during the period. Finally, Blue Trust Inc. raised its holdings in NeoGenomics by 33.2% during the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after buying an additional 1,103 shares during the period. Institutional investors own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Bank of America cut their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Needham & Company LLC cut their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Jefferies Financial Group began coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Piper Sandler dropped their price target on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.60.

NeoGenomics Trading Down 0.7 %

NeoGenomics stock opened at $9.86 on Friday. The stock has a 50-day moving average of $12.34 and a two-hundred day moving average of $14.57. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics, Inc. has a one year low of $8.98 and a one year high of $19.12. The stock has a market cap of $1.27 billion, a PE ratio of -15.90 and a beta of 1.28.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.